![](https://i.imgur.com/CLvY2jA.png")
It is now poised to agree a deal which would see both Valneva and Scottish Enterprise invest in the Livingston site.
Negotiations also include agreements for the company to supply Scotland with its VLA2001 Covid vaccine in future, subject to regulatory approval, and commitments to jobs for the future in Livingston.
Speaking at a meeting of the Science and Technology Committee, Dame Kate said the Valneva site in Livingston had “a whole-virus based manufacturing capability”, adding: “One of the things that we were keen to do was to make sure the UK has flexible, state-of-the-art manufacturing capability to deal with whatever potential current or future pandemic virus comes along.
"And so by cancelling the contract, that means we lose that capability.”
It is intended for active immunisation of at-risk populations and potentially later for routine vaccination, including addressing new variants. It may also be suitable for use as a booster.
David Lawrence, Acting Chief Financial Officer, said “Subject to regulatory approval we want to make VLA2001 available to people who need it, as soon as we can.
"We already have some vaccine stock available for distribution, upon approval.
https://www.heraldscotland.com/news/1980...t-backing/
Negotiations also include agreements for the company to supply Scotland with its VLA2001 Covid vaccine in future, subject to regulatory approval, and commitments to jobs for the future in Livingston.
Speaking at a meeting of the Science and Technology Committee, Dame Kate said the Valneva site in Livingston had “a whole-virus based manufacturing capability”, adding: “One of the things that we were keen to do was to make sure the UK has flexible, state-of-the-art manufacturing capability to deal with whatever potential current or future pandemic virus comes along.
"And so by cancelling the contract, that means we lose that capability.”
It is intended for active immunisation of at-risk populations and potentially later for routine vaccination, including addressing new variants. It may also be suitable for use as a booster.
David Lawrence, Acting Chief Financial Officer, said “Subject to regulatory approval we want to make VLA2001 available to people who need it, as soon as we can.
"We already have some vaccine stock available for distribution, upon approval.
https://www.heraldscotland.com/news/1980...t-backing/
